- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01839448
Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation (DG Post-Partum)
Frequency of Abnormal Glucose Metabolism (Diabetes, Impaired Glucose Tolerance, Impaired Fasting Glucose) in the Immediate Postpartum Period Following Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation
Study Overview
Status
Intervention / Treatment
Detailed Description
The secondary objectives of this study are to compare between the two groups:
A. the rate of type 2 diabetes only, glucose intolerance only, impaired fasting glucose only, and patients requiring insulin at 4-12 weeks postpartum
B. rates of maternal and obstetric complications
C. risk factors (age, body mass index, personal history of gestational diabetes or macrosomia, first degree family history of diabetes).
D. For fasting glucose done before 24SA, we will calculate the optimal threshold for predicting abnormal glucose metabolism in the immediate postpartum period among women with gestational diabetes.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Arles Cedex, France, 13637
- CH d'Arles - Hôpital Joseph Imbert
-
Montpellier, France, 34295
- CHU de Montpellier - Hôpital Lapeyronie
-
Montpellier Cedex 5, France, 34295
- CHU de Montpellier - Hôpital Arnaud de Villeneuve
-
Nîmes Cedex 9, France, 30029
- CHU de Nimes - Hopital Universitaire Caremeau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The patient must have given her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient is available for 10 months of follow-up
- The patient is pregnant and consulting before 24 weeks of amenorrhea AND has at least one of the following risk factors: age > 35 years; body mass index > 25; family history of type 2 diabetes; history of gestational diabetes; history of macrosomia.
- The patient has a fasting blood glucose level >= 0.92 g/l before 24 weeks of amenorrhea OR a fasting blood glucose level < 0.92 g/l before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test (75 g of glucose) between 24 and 28 weeks of amenorrhea (normal values are set at T0 < 0.92 g/l; T60 < 1.80 g/l; T120 < 1.53 g/l).
Exclusion Criteria:
- The patient is participating in another study
- The patient is in an exclusion period determined by a previous study, with the exception of the following studies: Papillo PMA (RCB 2013-A00538-37), LXRs (RCB 2009-A00968-49), GrossPath (RCB 2014-A01120-47), BAKRI (RCB 2013-A00914-41), OASIS II (RCB 2013-A00773-42), ElastoMAP (RCB 2013-A01148-37), ElastoDéclench (RCB 2014-A00828-39) and UpSideDown (RCB 2014-A01921-46).
- The patient is under judicial protection, under tutorship or curatorship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- The patient cannot read French
- The patient has a known history of type 2 diabetes
- The patient is diagnosed with type 2 diabetes during pregnancy (fasting blood glucose level > 1.26 g/l)
- The patient has a contra-indication for a treatment necessary for this study
- The patient is taking chronic or intermittent oral or inhaled corticosteroids, or a β2 agonist treatment for a previous disease or a disease discovered during pregnancy within one week preceding the fasting glucose or oral glucose tolerance test.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
GD diagnosis before 24 weeks
Patients in this group are diagnosed with gestational diabetes (GD) before 24 weeks of amenorrhea by means of a fasting blood glucose test >= 0.92 g/l. Intervention: Post-partum oral glucose tolerance test |
All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy.
Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
|
GD diagnosed at 24 to 28 weeks
Patients in this group are diagnosed with gestational diabetes between 24 and 28 weeks of amenorrhea based on a normal fasting blood glucose level before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test between 24 and 28 weeks of amenorrhea. Intervention: Post-partum oral glucose tolerance test |
All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy.
Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence/absence of abnormal glucose metabolism
Time Frame: 4 to12 weeks post-partum
|
Includes type 2 diabetes, glucose intolerance and impaired fasting glucose
|
4 to12 weeks post-partum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence/absence of type 2 diabetes
Time Frame: 4 to 12 weeks post partum
|
4 to 12 weeks post partum
|
|
Presence/absence of glucose intolerance
Time Frame: 4 to 12 weeks post-partum
|
4 to 12 weeks post-partum
|
|
Presence/absence of impaired fasting glucose
Time Frame: 4 to12 weeks post-partum
|
American definition: defined as between 1 and 1.26 g/l
|
4 to12 weeks post-partum
|
Presence/absence of impaired fasting glucose
Time Frame: 4 to12 weeks post-partum
|
European definition: defined as between 1.1 and 1.26 g/l
|
4 to12 weeks post-partum
|
Patient requiring insulin: yes/no
Time Frame: 4 to12 weeks post-partum
|
4 to12 weeks post-partum
|
|
Presence/absence of complications
Time Frame: 4 to12 weeks post-partum
|
This includes a yes/no response for each of the following: caesarean section, hypertension, preeclampsia, urinary tract infection, macrosomia, dystocia, neonatal transfer, respiratory distress, threat of premature birth.
|
4 to12 weeks post-partum
|
Baby's weight at birth (kg)
Time Frame: 4 to 12 weeks post-partum
|
4 to 12 weeks post-partum
|
|
Weeks of amenorrhea (duration of pregnancy in weeks/ gestational age)
Time Frame: 4 to 12 weeks post-partum
|
4 to 12 weeks post-partum
|
|
Patient was older than 35 years of age at beginning of pregnancy? yes/no
Time Frame: baseline (day 0)
|
baseline (day 0)
|
|
Body mass index > 25 at beginning of pregnancy? yes/no
Time Frame: baseline (day 0)
|
baseline (day 0)
|
|
First degree family history of type 2 diabetes? yes/no
Time Frame: baseline (day 0)
|
baseline (day 0)
|
|
History of gestational diabetes? yes/no
Time Frame: baseline (day 0)
|
baseline (day 0)
|
|
History of macrosomia? yes/no
Time Frame: baseline (day 0)
|
baseline (day 0)
|
|
Fasting glucose (g/l)
Time Frame: before 24 weeks of amenorrhea
|
before 24 weeks of amenorrhea
|
|
Oral glucose tolerance test results if necessary
Time Frame: 24 to 28 weeks of amenorrhea
|
24 to 28 weeks of amenorrhea
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Body mass index
Time Frame: baseline (day 0)
|
baseline (day 0)
|
Age
Time Frame: baseline (day 0)
|
baseline (day 0)
|
Number of pregnancies
Time Frame: baseline (day 0)
|
baseline (day 0)
|
Collaborators and Investigators
Investigators
- Study Director: Valéria Cosma, MD, Centre Hospitalier Universitaire de Nîmes
- Principal Investigator: Anne-Marie Guedj, MD, Centre Hospitalier Universitaire de Nîmes
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AOI/2012/VC-01
- 2013-A00277-38 (Other Identifier: RCB number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Intolerance
-
Yonsei UniversityNot yet recruitingType 2 Diabetes | Impaired Glucose Intolerance
-
University of California, IrvineUniversity of California, Davis; University of California, San FranciscoCompletedStress, Psychological | Pregnancy Related | Glucose Intolerance During PregnancyUnited States
-
Arizona State UniversityRecruiting
-
University of SaskatchewanRoyal University Hospital FoundationCompletedGlucose IntoleranceCanada
-
Glycemic Index Laboratories, IncDSM Nutritional Products, Inc.Completed
-
Materia Medica HoldingCompletedImpaired Glucose ToleranceRussian Federation
-
Joslin Diabetes CenterCompleted
-
TakedaCompletedImpaired Glucose ToleranceJapan
-
China Academy of Chinese Medical SciencesUnknownImpaired Glucose Tolerance
-
University of TromsoCompleted
Clinical Trials on Post-partum oral glucose tolerance test
-
Université de SherbrookeThe Lawson FoundationCompleted
-
University Hospital Schleswig-HolsteinUniversity of KielRecruitingParkinson Disease | Nutritional and Metabolic Diseases | Sugar IntakeGermany
-
University College DublinCompletedHealthy SubjectsIreland
-
NYU Langone HealthCompletedGlucose Metabolism Disorders | Diabetes Mellitus | Prediabetic State | Diabetes, GestationalUnited States
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Children's Hospital of PhiladelphiaCystic Fibrosis FoundationRecruitingCystic Fibrosis | Cystic Fibrosis-related DiabetesUnited States
-
Ankara City Hospital BilkentRecruitingGestational Diabetes | Glucose Intolerance During PregnancyTurkey
-
Christophe De BlockUnknownDiabetes Mellitus | Stress HyperglycemiaBelgium
-
Zhujiang HospitalRecruitingDiabetes Mellitus | Prediabetes | Gestational Diabetes Mellitus | ProteomicsChina
-
University of NottinghamCompletedGastrointestinal DysfunctionUnited Kingdom